- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Improving Care While Reducing Costs Through ACOs and Other Value-Based Efforts
Improving the quality of care while also reducing costs has become a centerpiece for transforming the US healthcare system. As efforts across the country continue to be introduced, accountable care organizations (ACOs) have emerged as an effective way to address these 2 issues.
Improving the quality of care while also reducing costs has become a centerpiece for transforming the US healthcare system. As efforts across the country continue to be introduced, accountable care organizations (ACOs) have emerged as an effective way to address these 2 issues. With recent CMS changes to their Medicare ACO program and growing interest from commerical payers, as well as demonstrated cost savings, the prevalence of these ACOs is likely to continue to spread across the healthcare system.
During this podcast, we speak with 3 experts about these ACOs, as well as other mechanisms of value-based care:
- Rob Mechanic, MBA, senior fellow at the Heller School of Social Policy and Management at Brandeis University and executive director of the Institute for Accountable Care
- Kim Kauffman, MPH, vice president of value-based care at Summit Medical Group
- Scott Hewitt, vice president, payment strategy and innovation, UnitedHealthcare
You may need to log in to the website to access this podcast.
Listen above or through one of these podcast services:
Read more on ACOs:
CMS Finalizes Overhaul of MSSP With Some Changes to Its Proposed Rule
Next Generation ACO Model Saves $62 Million in First Year
Are Commercial Payers Experiencing Success With ACO Partnerships?
Tying Social Determinants of ACO Patients With High-Need, High-Cost Care
ACOs Had No Significant Impact on Spending for Patients With Cancer
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More
